Hepatitis CSymptoms, Doctors, Treatments, Advances & More
Learn About Hepatitis C
View Main Condition: Hepatitis
Hepatitis C is a viral disease that leads to swelling (inflammation) of the liver.
Other types of viral hepatitis include:
- Hepatitis A
- Hepatitis B
- Hepatitis D
- Hepatitis E
Sustained virologic response - hepatitis C; SVR - hepatitis C
Hepatitis C infection is caused by the hepatitis C virus (HCV).
You can catch hepatitis C if the blood of someone who has HCV enters your body. Exposure may occur:
- After a needle stick or sharps injury
- If blood from someone who has HCV contacts a cut on your skin or contacts your eyes or mouth
- While injecting street drugs
- After a blood transfusion
People at risk for HCV are those who:
- Inject street drugs or share a needle with someone who has HCV
- Have been on long-term kidney dialysis
- Have regular contact with blood at work (such as a health care worker)
- Have unprotected sexual contact with a person who has HCV
- Were born to a mother who had HCV
- Received a tattoo or acupuncture with needles that were not disinfected properly after being used on another person (risk is very low with practitioners who have a tattoo license or permit or an acupuncture license)
- Received an organ transplant from a donor who has HCV
- Share personal items, such as toothbrushes and razors, with someone who has HCV (less common)
- Received a blood transfusion (rare in the United States since blood screening became available in 1992)
Most people who are recently infected with HCV do not have symptoms. Some people have yellowing of the skin (jaundice). Chronic infection often causes no symptoms. But fatigue, abdominal pain, depression and other problems can occur.
Persons who have long-term (chronic) infection often have no symptoms until their liver becomes scarred (cirrhosis). Many people with cirrhosis are ill and have many health problems.
The following symptoms may occur with HCV infection:
- Pain in the right upper abdomen
- Abdominal swelling due to fluid (ascites)
- Clay-colored or pale stools
- Dark urine
- Fatigue
- Fever
- Itching
- Jaundice
- Loss of appetite
- Nausea and vomiting
You should talk to your provider about your treatment options and when treatment should begin.
- The goal of treatment is to rid the body of the virus. This can prevent liver damage that may lead to liver failure or liver cancer.
- Treatment is especially important for people who are showing signs of liver fibrosis or scarring.
Antiviral medicines are used to treat HCV. These medicines help fight HCV. Newer antiviral medicines:
- Provide an excellent cure rate
- Have fewer side effects and are easier to take than older medicines
- Are taken by mouth for 8 to 24 weeks
The choice of which medicine depends on the genotype of HCV you have.
A liver transplant may be recommended for people who develop cirrhosis or liver cancer. Your provider can tell you more about liver transplant.
If you have HCV:
- Do not take over-the-counter medicines that you have not taken before without asking your provider. Also ask about vitamins and other supplements.
- Do not use alcohol or street drugs. Alcohol can speed up the damage to your liver. It can also reduce how well medicines work.
- If blood tests show that you do not have antibodies to hepatitis A and B, you should have the hepatitis A and hepatitis B vaccines. If you have not received a vaccine for hepatitis A or B or have not had these forms of hepatitis, you may need vaccination for them.
Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville
Mark Sulkowski, MD, is a Professor of Medicine at the Johns Hopkins University School of Medicine and the Director of the Division of Infectious Diseases at Johns Hopkins Bayview Medical Center. He also serves as the Medical Director of the Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology in the Department of Medicine and is the Senior Associate Dean for Clinical Trials. He received his MD from Temple University School of Medicine, Philadelphia, PA (1992), pursued training in Internal Medicine at Duke University School of Medicine, Durham, NC (1995) and completed his Fellowship in Infectious Diseases (1998) at the Johns Hopkins University School of Medicine. Prof. Sulkowski has been the principal investigator for more than 120 clinical trials related to the management of viral hepatitis B and C in persons with and without HIV co-infection. He was the global principal investigator for more than a dozen trials, including the largest clinical trial of agents for the treatment of hepatitis C (New England Journal of Medicine, 2009) and the vanguard study of combination therapy with direct inhibitors of the HCV NS5A and NS5B non-structural proteins (New England Journal of Medicine, 2014). He is the past-chair of the Hepatitis Transformative Sciences Group of the National Institute of Health-funded adult AIDS Clinical Trials Group (ACTG) where he led translational studies of liver disease, namely hepatitis B and C virus. He is an elected member of the American Society for Clinical Investigation (2011) and the American Association of Physicians (2017). Prof. Sulkowski is a member of numerous professional societies including the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the Infectious Diseases Society of America (IDSA). With more than 300 peer-reviewed articles, he is widely published with works in Annals of Internal Medicine, New England Journal of Medicine, JAMA, Clinical Infectious Diseases, Journal of Hepatology, and Hepatology. In 2017, 2018 and 2019, he was named as a Highly Cited Researcher (Clarivate Analytics) defined as the being in the top 1% of global researchers in 21 fields of the sciences and social sciences based on the number of citations for papers. As an invited lecturer, he has been frequently invited to present at major national and international medical congresses and has educated learners in more than 25 countries. Dr. Sulkowski is rated as an Elite provider by MediFind in the treatment of Hepatitis C. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Hepatitis C, Hepatitis, HIV/AIDS, and Hepatitis B. Dr. Sulkowski is board certified in American Board Of Internal Medicine.
Duke Gastroenterology Clinic - Clinic 2J
I am proud to serve as the Chief of the Duke Division of Gastroenterology. In addition to my administrative duties, I enjoy my clinical practice focused on the care of patients with liver diseases. I also continue to participate in clinical research and hope that these studies offer our patients the latest advances and treatment options. Dr. Muir is rated as an Elite provider by MediFind in the treatment of Hepatitis C. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Hepatitis C, Hepatitis, Sclerosing Cholangitis, Liver Transplant, and Kidney Transplant. Dr. Muir is board certified in American Board Of Internal Med, Gastroenterology and American Board Of Internal Med, Transplant Hepatology.
Johns Hopkins Bayview Medical Center
Dr. Oluwaseun O. Falade-Nwulia is an assistant professor of medicine at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include infectious disease. Dr. Falade-Nwulia earned her M.B.B.S. from the University of Ibadan Medical School College of Medicine. She completed her residency at Johns Hopkins Bayview Medical Center. She performed fellowships in infectious diseases at Johns Hopkins and a fellowship in critical care medicine at the National Institutes of Health. Dr. Falade is rated as an Elite provider by MediFind in the treatment of Hepatitis C. She is also highly rated in 3 other conditions, according to our data. Her clinical expertise encompasses Hepatitis C, Hepatitis, HIV/AIDS, and Sepsis. Dr. Falade is board certified in American Board Of Internal Medicine.
More information and support for people with HCV condition and their families can be found by joining a support group. Ask your provider about liver disease resources and support groups in your area.
Most people (75% to 85%) who are infected with the virus develop chronic HCV unless they get treatment for it. This condition poses a risk for cirrhosis and liver cancer. The outlook for HCV depends in part on the genotype.
A good response to treatment occurs when the virus can no longer be detected in the blood 12 weeks or more after treatment. This is called "sustained virologic response" (SVR). Up to 90% of those treated for some genotypes have this type of response.
Some people do not respond to the initial treatment. They may need to be re-treated with a different class of medicines.
Also, some people can become re-infected or infected with a different genotype strain of HCV.
Contact your provider if:
- You develop symptoms of hepatitis
- You believe you have been exposed to HCV
Steps that can be taken to help prevent the spread of HCV from one person to another include:
- Health care workers should follow precautions when handling blood.
- Do not share needles with anyone.
- Do not get tattoos or body piercings or receive acupuncture from someone who does not have a permit or license.
- Do not share personal items, such as razors and toothbrushes.
- Practice safer sex.
If you or your sexual partner is infected with HCV and you have been in a stable and monogamous (no other partners) relationship, the risk of giving the virus to, or getting the virus from, the other person is low.
HCV cannot be spread by casual contact, such as holding hands, kissing, coughing or sneezing, breastfeeding, sharing eating utensils or drinking glasses.
Currently there is no vaccine for HCV.
Summary: The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) in participants taking either prescribed or illicit drugs.
Summary: The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
Published Date: April 21, 2025
Published By: Todd Eisner, MD, Private practice specializing in Gastroenterology in Boca Raton and Delray Beach, Florida at Gastroenterology Consultants of Boca Raton. Affiliate Assistant Professor, Florida Atlantic University School of Medicine. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Bhattacharya D, Aronsohn A, Price J, Lo Re V; AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2023 Update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. Published online May 25, 2023. PMID: 37229695 pubmed.ncbi.nlm.nih.gov/37229695/.
Centers for Disease Control and Prevention. Hepatitis C. Hepatitis C basics. www.cdc.gov/hepatitis-c/about/. Updated January 31, 2025. Accessed May 19, 2025.
Holmes JA, Chung RT. Hepatitis C. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 11th ed. Philadelphia, PA: Elsevier; 2021:chap 80.
Naggie S, Wyles DL. Hepatitis C. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Philadelphia, PA: Elsevier; 2020:chap 154.
Pawlotsky J-M. Chronic viral and autoimmune hepatitis. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 135.